BOLETÍN HTA

61 / 88

HIPERTENSIÓN / 2015 / VOL. 20
59
Bibliografía
1. National Institute for Health and Clinical Excellence. Hypertension: clinical management of primary hypertension in adults. CG127. 2011. http://guidance
2. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B; on behalf of the Guideline Development Group. Management of hypertension: summary of
NICE guidance. BMJ 2011; 343:d4891.
3. Campbell NC, Murchie P. Treating hypertension with guidelines in general practice: Patients decide how low they go, not targets. BMJ 2004; 329:523-4.
4. Ritchie LD, Campbell NC, Murchie P. New NICE guidelines for hypertension: Ambulatory monitoring is to become key. BMJ 2011; 343:d5644.
5. ISD Scotland. Prescribing and medicines: prescription cost analysis 2010/2011. www.
Publications/2011-06-28/2011-06-28-PrescribingCosts-Report.pdf? 30967348815.
6. Hodgkinson J, Mant J, Martin U, et al. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure
monitoring in diagnosis of hypertension: systematic review. BMJ 2011; 342:d3621.
7. Lovibond K, Jowett S, Barton P. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet 2011;
online 23 August; doi: 10. 1016/S0130-6736 (11) 61299-3.
8. Verdecchia P. Prognostic value of ambulatory blood pressure: current evidence and clinical implications. Hypertension 2000; 35:844-51.
9. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension.
Systolic Hypertension in Europe Trial Investigators. JAMA 1999; 282:539-46.
10. Glynn LG, Murphy AW, Smith SM, Schroeder K, Fahey T. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane
Database Syst Rev 2010; 3:CD005182.
11. Pickering TG, Shimbo D, Haas D. Ambulatory blood pressure monitoring. N Engl J Med 2006; 354:2368-74.
12. Gaziano TA. Accurate hypertension is key in efficient control. Lancet 2011; online 23 August; doi: 10.1016/S0140-6736 (11) 61299-3.
13. Sofat R, Casas JP, Grosso AM, et al. Could NICE guidance on the choice of blood pressure lowering drugs be simplified? BMJ 2012; 344:d8078.
14. Mac Manus R, Caulfield M, Williams B. NICE hypertension guideline 2011: evidence based evolution. BMJ 2012; 344: e181.
15. Jackson R, Barham P, Bills J, Birch T, et al. Management of raised blood pressure in New Zealand: a discussion document. BMJ 1993; 307:107-10.
16. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010; 375:938-48.
17. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;
359:2417-28.
18. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required
versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-blood pressure lowering arm (ASCOT-BPLA): a
multicentre randomised controlled trial. Lancet 2005; 366:895-906.
19. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of
102 prospective studies. Lancet 2010; 375:2215-22.
20. Williams B, MacDonald TM, Morant S, et al, for The British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol,
and doxazosin to determine the optimal treatment for drug -resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;
published online Sept 21. . org/10.1016/S0140-6736 (15) 00257-3.